Clinical data confirms earlier results for MiStent SES in coronary artery disease- Micell technologies

Micell Technologies announced four-year clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent sirolimus eluting absorbable polymer coronary stent system (MiStent SES) in patients with coronary artery disease. Highlights of the data included no target lesion events in the DESSOLVE I study and sustained clinical outcomes in both DESSOLVE I and II through four years' follow-up.

There have been no probable or definite stent thromboses in either study. Importantly, the MiStent SES continues to show a low combined target lesion revascularisation (TLR) rate for DESSOLVE I and II of 2.7% at 4 years' follow-up, which is consistent with previously demonstrated lack of late loss progression in the DESSOLVE I study. Data were presented at the 27th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference.

Comment: In 2015, clinical sites in Europe and China began enrolling patients in DESSOLVE III and DESSOLVE C, respectively. DESSOLVE III is a prospective, randomised, balanced, controlled, single-blind, multi-centre study comparing clinical outcomes between MiStent SES and Xience in a 'real world, all-comers' patient population. DESSOLVE C is a prospective, randomised, controlled, single-blind, multi-centre clinical trial to demonstrate MiStent SES' efficacy and safety.